Sickle Cell Hemoglobin C
6
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
Pharmacokinetics of Oral Hydroxyurea Solution
Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App
Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study